News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

China Medical Systems Invests $8 Million In Destiny; Will Acquire Asia Rights For MRSA Candidate



9/11/2017 11:35:04 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
China Medical Systems of Shenzhen will gain Asia rights (ex-Japan) to a MRSA candidate from Destiny Pharma, a British company specializing in treatments for drug resistant infections. CMS contributed $4 million to Destiny's recent $20.6 million IPO on London's AIM exchange, and its parent added another $4 million. In return, CMS and Destiny have signed a binding framework agreement giving CMS the rights to develop and commercialize Destiny's MRSA treatment, XF-73, in Asia.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES